Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Y320 suppresses non-small cell lung cancer growth by triggering autophagy-dependent pyroptosis through ubiquitin/proteasome-mediated c-FLIP degradation.

European journal of pharmacology·2026
Same author

Combining Online HPLC-ABTS Screening With Machine Learning to Predict the Bioactivity of Antioxidant Components in Pandani Tectorii Radix et Rhizoma.

Biomedical chromatography : BMC·2026
Same author

Application of small interfering RNAs and drug combination for pancreatic cancer therapy.

Journal of drug targeting·2026
Same author

Biosynthesis of L-Pipecolic Acid and Its Hydroxylated Derivatives: Enzyme, Engineering, and Synthesis Method.

Biotechnology and bioengineering·2026
Same author

Development and validation of a machine learning model to predict early recurrence after surgery in NSCLC patients.

Scientific reports·2025
Same author

Novel E-F ring derivatives of aconitine scaffold as potent Hsp90 inhibitors for the treatment of colorectal cancer.

European journal of medicinal chemistry·2025

Related Experiment Video

Updated: May 27, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

[Lidamycin metabolism in vitro].

Yan-qing Wen1, Zhi-yun Meng, Shu-zhen Chen

  • 1Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, China.

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|November 30, 2011
PubMed
Summary

Lidamycin shows varied metabolism across species in vitro. Human lidamycin metabolism in plasma resembles that in dogs, with minimal impact on cytochrome P450 enzymes, suggesting no drug interactions.

More Related Videos

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Experiment Videos

Last Updated: May 27, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Biochemistry
  • Analytical Chemistry

Context:

  • Understanding drug metabolism is crucial for effective clinical therapy and predicting potential drug-drug interactions.
  • Lidamycin's metabolic profile across different species and its interaction with key drug-metabolizing enzymes (cytochrome P450) require elucidation.
  • In vitro studies using plasma and liver microsomes provide a foundational understanding of drug disposition.

Purpose:

  • To investigate the in vitro metabolism of lidamycin in plasma and liver microsomes from various species (rat, dog, monkey, human).
  • To determine the metabolic stability of lidamycin and its potential inhibition of human cytochrome P450 isoforms.
  • To guide clinical therapy by understanding lidamycin's metabolic fate and predicting interactions with other medications.

Summary:

  • Lidamycin was quantified using High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS).
  • Metabolic rates in plasma varied by species: rat > dog > human > monkey. Lidamycin was only metabolized in monkey liver microsomes.
  • No significant inhibition of cytochrome P450 isoforms was observed at tested concentrations, indicating a low risk of pharmacokinetic interactions.

Impact:

  • Lidamycin's metabolic profile in humans is comparable to that in dogs.
  • Co-administration of lidamycin with other drugs is unlikely to decrease the metabolism of those drugs via cytochrome P450 pathways.
  • These findings support the safe clinical use of lidamycin by predicting minimal drug-drug interactions related to cytochrome P450 metabolism.